TaiMed Biologics Inc.

Taipei Exchange 4147.TWO

TaiMed Biologics Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -111.17

TaiMed Biologics Inc. Price to Earnings Ratio (P/E) is -111.17 on January 14, 2025, a 3.79% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

TaiMed Biologics Inc. 52-week high Price to Earnings Ratio (P/E) is -86.61 on August 06, 2024, which is 22.09% above the current Price to Earnings Ratio (P/E).
TaiMed Biologics Inc. 52-week low Price to Earnings Ratio (P/E) is -145.55 on February 27, 2024, which is -30.93% below the current Price to Earnings Ratio (P/E).
TaiMed Biologics Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -110.93.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Taipei Exchange: 4147.TWO

TaiMed Biologics Inc.

CEO	Mr. Chin-Ming Chang Ph.D.
IPO Date	June 20, 2012
Location	Taiwan
Headquarters	No. 607, Ruiguang Road
Employees	79
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years